Oncology Medical News about Osteosarcoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study
Clinical Orthopedics and Related Research, 04/01/09

Urakawa H et al. - In a trial to determine whether cyclooxygenase-2 (COX-2) overexpression predicts poor survival in pts with high-grade extremity osteosarcoma, preliminary data suggest COX-2 overexpression in the primary tumor correlates with occurrence of distant metastasis in pts with osteosarcoma and also may affect postmetastatic survival.

Methods

Expression levels of COX-2 were examined immunohistochemically in 51 pts with extremity osteosarcoma who completed standard therapy and obtained complete initial regression of the tumor.
Correlation of the positivity of staining with prognosis was analyzed.

Results

COX-2 was expressed in most of the cases.
No correlation was found between COX-2 staining intensity and variables such as gender, age, anatomic site, necrosis after chemotherapy, and surgical stage.
Strong COX-2 expression was associated with low metastasis-free survival.
Age >20 yrs and strong COX-2 expression independently predicted increased risk of metastasis.
Among 7 pts with resectable lung metastasis, all 3 with greater COX-2 expression in the metastatic lesion than that in a primary site died of the disease.

<< Previous
Adjuvant imatinib mesylate after resection of localised, primary...

Next >>
Estramustine plus docetaxel as second-line therapy in patients...